New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
07:33 EDTADXSAdvaxis announces presentation of updated ADXS-cHER2 data
Advaxis announced that its principal investigator presented updated data from the ongoing ADXS-cHER2 study in canine osteosarcoma at the 2014 American College of Veterinary Internal Medicine Forum. The preliminary findings of the Phase 1 clinical trial in dogs with osteosarcoma suggest that ADXS-cHER2 is safe and well tolerated at doses up to 3 x 109 CFU with no evidence of cardiac, hematological, or other systemic toxicities. The study determined that ADXS-cHER2 is able to delay or prevent metastatic disease and significantly prolong overall survival in dogs with osteosarcoma that had minimal residual disease following standard of care. At the time of the presentation, 80% of the dogs treated were still alive and median survival had not yet been reached. Median survival in control dogs was 316 days. Immunological analyses are also being conducted in this study to further evaluate the immune response to ADXS-cHER2. Recently, ADXS-cHER2 was granted orphan drug status for the treatment of human osteosarcoma by the U.S. Food and Drug Administration Office of Orphan Products Development.
News For ADXS From The Last 14 Days
Check below for free stories on ADXS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 9, 2014
07:43 EDTADXSAdvaxis provides clinical development updatefor ADXS-HPV
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use